Stock TLSA TIZIANA LIFE SCIENCES LTD
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Tiziana Life Sciences Ltd

Equities

TLSA

BMG889121031

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
0.919 USD +13.47% Intraday chart for Tiziana Life Sciences Ltd +12.07% +64.11%
May. 10 Tiziana Life Sciences Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apr. 25 Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
AQ
MEDIA: MS News Today: Foralumab found to ease fatigue in SPMS patients in access program
PU
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
AQ
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
AQ
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today
AQ
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
AQ
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
AQ
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
AQ
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
AQ
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
AQ
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
AQ
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
AQ
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
AQ
Tiziana Life Sciences : Updated Interim Results for the Six Months Ended 30 June 2023 - Form 6-K
PU
Tiziana Life Sciences : Interim Results for the Six Months Ended 30 June 2023 863.7 KB
PU
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
AQ
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
AQ
Tiziana Life Sciences : Notice of Annual General Meeting of Shareholders on Thursday 14th December 2023 at 8.30am EST/ 1.30pm UK - Form 6-K
PU
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
AQ
Tiziana Life Sciences : Notice of Annual General Meeting December 2023
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TLSA Stock
  4. News Tiziana Life Sciences Ltd
  5. Press Releases